The investigational drug demonstrated robust STAT6 degradation in blood and skin that was well tolerated and safe in healthy ...

Kymera Therapeutics reported positive results from its phase 1 healthy volunteer study using KT-621. Click here to find out ...

Since the European Medicines Agency (EMA) approval of omalizumab in 2005 as the first ever biologic for severe asthma, the ...

If you or someone you know has chronic asthma do read this article to know how biologics can potentially help in treating the condition ...

Children with uncontrolled, moderate to severe asthma used dupilumab or placebo for 52 weeks. The treatment group had significant decreases in annualized exacerbation rates compared with the ...

Dupilumab reduced airway inflammation and mucus burden and enhanced airway volume and flow, which led to better lung function and improved asthma control in patients with moderate to severe type 2 ...

Three abstracts evaluating dupilumab (Dupixent) for moderate-to-severe asthma were presented at the recent American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting: VESTIGE ...

Dupilumab shows long-term efficacy across yearly seasons in patients with type 2 inflammatory asthma. Patients with type 2 inflammatory asthma, with and without evidence of allergic asthma ...

Perspective from Tania Elliott, MD HONOLULU — Patients with well-controlled asthma who use dupilumab may tolerate a reduction in the frequency of their doses from every 2 weeks to every 4 weeks ...

Posters presented at ACAAI 2023 Annual Scientific Congress examined dupilumab use in children with moderate-to-severe asthma and in the presence of elevated type 2 biomarkers. Two posters ...